High-grade gliomas (HGG) are a devastating group of cancers, and represent the leading cause of brain tumour-related death in both children and adults. Therapies aimed at mechanisms intrinsic to glioma cells have translated to only limited success; effective therapeutic strategies will need also to target elements of the tumour microenvironment that promote glioma progression. Neuronal activity promotes the growth of a range of molecularly and clinically distinct HGG types, including adult and paediatric glioblastoma (GBM), anaplastic oligodendroglioma, and diffuse intrinsic pontine glioma (DIPG) 1 . An important mechanism that mediates this neural regulation of brain cancer is activitydependent cleavage and secretion of the synaptic adhesion molecule neuroligin-3 (NLGN3), which promotes glioma proliferation through the PI3K-mTOR pathway 1 . However, the necessity of NLGN3 for glioma growth, the proteolytic mechanism of NLGN3 secretion, and the further molecular consequences of NLGN3 secretion in glioma cells remain unknown. Here we show that HGG growth depends on microenvironmental NLGN3, identify signalling cascades downstream of NLGN3 binding in glioma, and determine a therapeutically targetable mechanism of secretion. Patient-derived orthotopic xenografts of paediatric GBM, DIPG and adult GBM fail to grow in Nlgn3 knockout mice. NLGN3 stimulates several oncogenic pathways, such as early focal adhesion kinase activation upstream of PI3K-mTOR, and induces transcriptional changes that include upregulation of several synapse-related genes in glioma cells. NLGN3 is cleaved from both neurons and oligodendrocyte precursor cells via the ADAM10 sheddase. ADAM10 inhibitors prevent the release of NLGN3 into the tumour microenvironment and robustly block HGG xenograft growth. This work defines a promising strategy for targeting NLGN3 secretion, which could prove transformative for HGG therapy.
acute cortical slices from Nlgn3 wild-type or transgenic knockout Thy1::ChR2 mice demonstrated that the increase in glioma cell proliferation induced by active conditioned medium is incompletely abrogated in the context of the Nlgn3 knockout (Extended Data Fig. 2a ), replicating the degree of differential proliferation previously accounted for by activity-regulated BDNF 1 . Taken together, these findings indicate that glioma growth is more dependent on NLGN3 in vivo than would have been predicted from these in situ/in vitro experiments.
The nearly normal neurological function of Nlgn3 knockout mice 3-5 is attributed to the compensatory expression of other neuroligins 2, 6 . We found no effect of NLGN1, NLGN4X, NLGN4Y (Extended Data Fig. 2b , c) or NLGN2 1 on glioma proliferation. Thus, compensatory expression of other neuroligins would not be expected to influence glioma growth, supporting a unique role for NLGN3 in glioma pathobiology.
To determine the role of NLGN3 in the growth of additional HGG types, patient-derived xenografts of DIPG (SU-DIPG-VI and SU-DIPG-XIII-FL) and adult glioblastoma (SU-GBM035) were tested in the Nlgn3-deficient mouse brain. We found that DIPG, xenografted to pons or to frontal cortex, and adult glioblastoma each exhibited marked growth stagnation in Nlgn3 knockout mice ( Fig. 1g-k) . By contrast, patient-derived HER2 + breast cancer brain metastasis xenografts (DF-BM354) 7 did not exhibit differential growth in wild-type or knockout Nlgn3 mouse brains (Fig. 1l) . These results indicate a conserved dependency on NLGN3 across molecularly and clinically distinct types of HGG.
The observed growth inhibition is more profound than can be explained by known effects of NLGN3 on glioma PI3K-mTOR signalling 1 . To delineate the signalling consequences of NLGN3 exposure in glioma better, we used phosphoproteomics ( Fig. 2a , Extended Data Table 1 ). Phospho-antibody array analyses at 5 and 30 minutes after NLGN3 exposure revealed focal adhesion kinase (FAK) phosphorylation and numerous phosphorylation events classically downstream of FAK, including activation of the SRC kinase cascade, PI3K-mTOR cascade, and SHC-RAS-RAF-MEK-ERK cascade ( Fig. 2a ). Additional oncogenic proteins exhibiting increased phosphorylation include integrin β 3, growth factor receptors EGFR, FGFR and VEGFR, and others (Extended Data Table 1 ). FAK activity is central to many of these signalling events. Phospho-tyrosine pull-down analysis at 5-min after NLGN3 exposure similarly demonstrated FAK phosphorylation. FAK inhibition blocked the effects of NLGN3 on glioma proliferation (Fig. 2b, c) . FAK phosphorylation peaked at 5-10 min after NLGN3 exposure, placing FAK early in the signalling cascade ( Fig. 2d ). FAK activity was necessary for PI3K stimulation by NLGN3 as demonstrated by AKT (Ser473) phosphorylation ( Fig. 2e ).
We performed RNA sequencing (RNA-seq) after glioma exposure to NLGN3. Genes involved in cell proliferation were upregulated, as were several genes known to promote malignancy in glioma, including letter reSeArCH PDGFA [8] [9] [10] , TTYH1 11 and several potassium channel genes 12 (Extended Data Fig. 3 ). In addition to NLGN3 1 , numerous genes involved in synapse function were upregulated after exposure to NLGN3 (Extended Data Fig. 3 ). While the meaning of this intriguing observation remains to be clarified, it suggests the biology of NLGN3 may extend beyond the role of mitogen.
The notable inhibition of glioma growth observed in the Nlgn3deficient mouse brain highlights its therapeutic potential. Blocking release into the tumour microenvironment is one therapeutic strategy, so we sought to determine the proteolytic and cellular details of NLGN3 shedding. Full-length NLGN3 is cleaved and secreted in an activityregulated fashion with shedding of the N-terminal ectodomain 1 (Fig. 3a-c) . Optogenetic stimulation of acute cortical slices increased NLGN3 shedding, whereas the addition of tetrodotoxin (TTX) inhibited NLGN3 shedding (Fig. 3c ).
Neuroligin-3 is highly expressed in both neurons and oligodendrocyte precursor cells 13 (OPCs; Extended Data Fig. 4a ), known to form bona fide synapses with pre-synaptic neurons and serve as a postsynaptic cell [14] [15] [16] . To test the relative contribution of neurons and OPCs to secretion of NLGN3, mice expressing cell type-specific, inducible Cre drivers were bred to Nlgn3 fl/fl mice. Tamoxifen was administered for 5 days starting at P28, and resulted in recombination in approximately 40% of cortical neurons in the CamKIIα -CreER driver mouse (in which expression of tamoxifen-activated CreER recombinase is driven by a Camk2a promoter), and in around 80% of OPCs in the PDGFRα -CreER driver mouse (Extended Data Fig. 4b, c ). Using the acute slice model together with inducible, conditional deletion of Nlgn3 from either neurons or OPCs, we find that both cell types contribute to activity-regulated NLGN3 secretion, and notably OPCs are a major source of secreted NLGN3 (Fig. 3d, e ), defining a role for OPCs as a microenvironmental cell type contributing to glioma growth.
NLGN3 exposure results in feed-forward glioma expression of NLGN3 1 , and we thus asked whether glioma cells contribute to the pool of secreted NLGN3. Increased levels of NLGN3 were found in conditioned medium from glioma xenograft-bearing, Nlgn3 wild-type brain slices compared to non-xenograft-bearing slices (Extended Data Fig. 5a, b ). Conditioned medium from NLGN3-primed glioma cultures also exhibit upregulated secretion (Extended Data Fig. 5c ). By contrast, xenograft-bearing brain slices from Nlgn3 knockout mice secrete no detectable NLGN3 (Extended Data Fig. 5b ). These data indicate that glioma cells contribute to NLGN3 in the tumour microenvironment in a manner regulated by neuroligin-3 exposure from normal stromal cells.
To determine the enzyme responsible for the cleavage of NLGN3, we analysed the C-terminal transmembrane domain for putative cleavage letter reSeArCH sites (https://prosper.erc.monash.edu.au/home.html). This indicated MMP and ADAM family proteases as candidate enzymes, a prediction consistent with the reported enzyme(s) responsible for NLGN1 cleavage 17, 18 and neural ADAM10 targets 19 . Active slice conditioned medium generated in the absence and presence of various protease inhibitors exhibited decreased NLGN3 shedding with MMP9 and ADAM10 inhibitors ( Fig. 3f , g). Increased full-length NLGN3 was observed in brain slice lysate concomitant with the observed decrease in cleaved NLGN3 in conditioned medium with either MMP9 or ADAM10 inhibitors ( Fig. 3g ). ADAM10 inhibition blocks NLGN3 shedding in a dose-dependent manner ( Fig. 3h ). Neither protease inhibitor directly affects glioma proliferation despite intrinsic expression of ADAM10 (Extended Data Figs 5d and 6b, c). However, decreased NLGN3 levels in active conditioned medium in response to protease inhibition elicit correspondingly reduced proliferation of exposed glioma cells (Extended Data Fig. 6a-d) , and add back of NLGN3 rescues proliferation (Extended Data Fig. 6d ). MMP9 and ADAM10 thus emerge as candidate enzymes that mediate NLGN3 cleavage.
Given the possibility of cross-inhibition with pharmacological protease inhibition, genetic models were used to definitively determine the proteolytic mechanism. Acute cortical slices from Mmp9 knockout mice showed no change in NLGN3 secretion ( Fig. 3i ), suggesting that MMP9 is not responsible for NLGN3 cleavage. Conditional knockout of Adam10 from CamKIIα + neurons resulted in an approximately 50% decrease in levels of secreted NLGN3 (Fig. 3j ), whereas conditional deletion of Adam10 from OPCs did not influence NLGN3 secretion ( Fig. 3k ). Incubation with TTX substantially abrogates ADAM10 release into active slice conditioned medium ( Fig. 3l ), demonstrating activity-regulated release of ADAM10, a finding consistent with reports of ADAM10 localized to synaptic vesicles 20 . Taken together, these data indicate that ADAM10, released in activity-dependent fashion from neurons, is the chief enzyme responsible for NLGN3 shedding.
We next investigated the therapeutic potential of ADAM10 inhibition. ADAM10 is expressed in gliomas as reported in the literature 21, 22 and demonstrated in gene expression datasets from paediatric and adult HGG samples (Extended Data Fig. 5d ). Cell-intrinsic effects of ADAM10 inhibition have been reported in adult HGG [22] [23] [24] , so we assessed possible direct effects of ADAM10 inhibition on the paediatric HGG cells used here. ADAM10 inhibition did not change proliferation, cell viability or invasion of paediatric HGG cells (Extended Data Fig. 6e -g). ADAM10 inhibition mildly affected paediatric HGG selfrenewal (Extended Data Fig. 6h , i).
We next tested the influence of ADAM10 inhibition on HGG growth in vivo. Brain penetration of the specific ADAM10 inhibitor GI254023X was assessed and found to be sufficient (Extended Data Table 2 ). Given the effects of ADAM10 inhibition on glioma selfrenewal and therefore tumour initiation, drug treatment started well after engraftment. Mice bearing paediatric glioblastoma (SU-pcGBM2) or DIPG (SU-DIPG-VI or SU-DIPG-XIX) orthotopic xenografts were treated with GI254023X or vehicle control. Paediatric GBM and both DIPG xenografts in mice treated with the ADAM10 inhibitor exhibited pronounced growth reduction compared to vehicle-treated controls ( Fig. 4a-c ). Histological analyses revealed reduced glioma proliferation in ADAM10 inhibitor-treated animals ( Fig. 4d , e and Extended Data Fig. 7a ). Furthermore, ADAM10 inhibition abrogated glioma cell secretion of NLGN3 from both xenograft-bearing brain slices and NLGN3-primed glioma cells (Extended Data Fig. 5b , c), suggesting that this therapeutic strategy addresses all cellular sources of NLGN3.
ADAM10 inhibitors have been developed for clinical use, and the ADAM10/17 inhibitors INCB7839 and XL-784 have been through phase II clinical trials for other diseases 25, 26 . Brain penetration of INCB7839 was superior to XL-784 ( Fig. 4f and Extended Data Fig. 7b ) and sufficient to inhibit ADAM10 enzymatic function 25, 26 (Fig. 4f ). INCB7839 robustly inhibited the growth of paediatric GBM orthotopic xenografts ( Fig. 4g ). ADAM10 mediates the cleavage of several cell letter reSeArCH surface proteins, prominently targeting synapse-associated proteins 19 , and also has an important role in amyloid protein processing 27 . While ADAM10 inhibition appears well-tolerated in clinical trials 25, 26 , and caused no overt neurotoxicity here (Extended Data Fig. 8 ), long-term effects on neurological function should be carefully evaluated.
The dependency of HGG growth on microenvironmental NLGN3 is conserved across several classes of paediatric and adult HGG (Supplementary Note 1). The magnitude of this effect both underscores its potential as a therapeutic target and suggests that the mechanisms by which NLGN3 promotes HGG growth ( Fig. 4h ) are incompletely understood. Future work will need to determine further mechanisms by which NLGN3 regulates glioma progression and clarify how the cancer may circumvent this dependency. Targeting the ADAM10 sheddase represents a potentially transformative strategy to modulate NLGN3 levels in the tumour microenvironment for HGG therapy.
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MethOdS
Mice and housing conditions. All in vivo experiments were conducted in accordance with protocols approved by the Stanford University Institutional Animal Care and Use Committee (IACUC) and performed in accordance with institutional guidelines. Animals were housed according to standard guidelines with free access to food and water in a 12 h light/12 h dark cycle. For brain tumour xenograft experiments, the IACUC does not set a limit on maximal tumour volume but rather on indications of morbidity; mice were euthanized if they exhibited signs of neurological morbidity or if they lost 15% or more of their body weight.
For constitutive Nlgn3 knockout studies, Nlgn3 knockout mice (The Jackson Laboratory) were intercrossed with NSG mice (non-obese diabetic (NOD)-severe combined immunodeficiency (SCID) Il2rg −/− (NSG); The Jackson Laboratory) to produce the Nlgn3 knockout;NSG genotype. All Nlgn3 mouse model experiments were performed with male mice, either hemizygous wild-type Nlgn3 (Nlgn3 y/+ ;NSG) or hemizygous null Nlgn3 littermates (Nlgn3 y/− ;NSG).
For conditional knockout experiments, Nlgn3 fl/fl mice (a gift from T. Sudhof) or Adam10 fl/fl mice (The Jackson Laboratory) were crossed to CamKIIα -CreER (The Jackson Laboratory) or PDGFRα -CreER (The Jackson Laboratory). Cre + or control Cre − floxed mice were treated with 100 mg kg −1 tamoxifen intraperitoneally for 5 days and experiments were performed 7 days after the end of treatment. Tamoxifen was given from postnatal day 28 (P28) to P33 and brain slice experiments performed at P40.
Mmp9 −/− mice (The Jackson Laboratory) were used in brain slice experiments at P40. Thy1::ChR2 (Jackson Labs, line 18) were used in brain slice experiments at 4-7 weeks of age. Bioluminescence imaging. For in vivo monitoring of tumour growth, bioluminescence imaging was performed using an IVIS imaging system (Xenogen). Mice orthotopically xenografted with luciferase-expressing glioma cells were placed under isofluorane anaesthesia and injected with luciferin substrate. Animals were imaged at baseline and randomized based on tumour size by a blinded investigator so that experimental groups contained an equivalent range of tumour sizes. All total flux values were then normalized to baseline values to determine fold change of tumour growth. Statistical analysis between tumour burden in each group was assessed using Student's two-tailed t-test (parametric data) or Mann-Whitney test (non-parametric data). On the basis of the variance of xenograft growth in control mice, we used at least 3 mice per genotype to give 80% power to detect an effect size of 20% with at a significance level of 0.05. Orthotopic xenografting. Patient-derived DIPG cells (SU-DIPG-VI, from a pontine DIPG tumour or SU-DIPG-XIII-FL, from a frontal lobe DIPG metastasis), paediatric glioblastoma cells (SU-pcGBM2 cells), adult glioblastoma cells, (SU-GBM035 cells) or HER2 + breast cancer brain meta stasis cells (DF-BM354 cells) expressing firefly luciferase were xenografted into the orthotopic location of derivation in Nlgn3 y/+ ;NSG and Nlgn3 y/− ;NSG mice. A single-cell suspension from cultured neurospheres was prepared in sterile PBS immediately before the xenograft procedure. Animals at P34-P36 were anaesthetized with 1-4% isoflurane and placed in a stereotactic apparatus. The cranium was exposed via midline incision under aseptic conditions. 600,000 glioma cells in 3 μ l sterile PBS were stereotactically implanted in either the premotor cortex (M2) (SU-pcGBM2, SU-DIPG-XIII-FL and SU-GBM035) or the pons (SU-DIPG-VI and SU-DIPG-XIX) through a 31-gauge burr hole, using a digital pump at infusion rate of 0.4 μ l min −1 and 31-gauge Hamilton syringe. For breast cancer brain metastasis studies, 100,000 DF-BM354 cells were similarly xenografted in the premotor cortex. Stereotactic coordinates used were as follows: for premotor cortex, 0.5 mm lateral to midline, 1.0 mm anterior to bregma, − 1.75 mm deep to cranial surface; for pons, 1.0 mm lateral to midline, − 0.8 mm posterior to lambda, − 5.0 mm deep to cranial surface. At the completion of infusion, syringe needle was allowed to remain in place for a minimum of 2 min, then manually withdrawn at a rate of 0.875 mm min −1 to minimize backflow of the injected cell suspension. Perfusion and immunohistochemistry. Animals were anaesthetized with intraperitoneal Avertin (tribromoethanol), then transcardially perfused with 20 ml of PBS. Brains were fixed in 4% paraformaldehyde overnight at 4 °C, then transferred to 30% sucrose for cryoprotection. Brains were embedded in Tissue-Tek OCT (Sakura) and sectioned in the coronal plane at 40 μ m using a sliding microtome (Microm HM450; Thermo Scientific). For immunohistochemistry, coronal sections were incubated in blocking solution (3% normal donkey serum, 0.3% Triton X-100 in TBS) at room temperature for 30 min. Chicken anti-GFP (1:500, Abcam), rat anti-MBP (1:300, Abcam), mouse anti-human nuclei clone 235-1 (1:100; Millipore), rabbit anti-Ki67 (1:500; Abcam), rabbit anti-cleaved caspase 3 (1:200, Cell Signaling), or mouse anti-NeuN (Millipore, 1:2,000) were diluted in 1% blocking solution (1% normal donkey serum in 0.3% Triton X-100 in TBS) and incubated overnight at 4 °C. Sections were then rinsed three times in 1× TBS and incubated in secondary antibody solution (Alexa 488 donkey anti-chicken IgG, 1:500 (Jackson Immuno Research); Alexa 594 donkey anti-mouse IgG, 1:500 (Life Technologies); Alexa 647 donkey anti-rabbit IgG, 1:500 (Life Technologies); Alexa 594 donkey anti-rat IgG, 1:1,000 (Life Technologies)) in 1% blocking solution at 4 °C overnight. Sections were rinsed three times in TBS and mounted with ProLong Gold Mounting medium (Life Technologies). Cell culture. For all human tissue studies, informed consent was obtained and tissue was used in accordance with protocols approved by the Stanford University or Dana Farber Cancer Institute Institutional Review Board (IRB). For all patient-derived cultures, short tandem repeat (STR) DNA fingerprinting was performed every three months to verify authenticity. The STR fingerprints and clinical characteristics for the patient-derived cultures used have been previously reported 1 with the exception of SU-DIPG-XIX which is a H3.3K27M mutant tumour that was derived from the brainstem at the time of autopsy from a male who was 2 years of age at diagnosis, treated with radiotherapy and cabazitaxel, and survived 18 months. STR fingerprint for SU-DIPG-XIX is: X/Y (AMEL), 10/11 (CSF1PO1), 13/14 (D13S317), 9/13 (D16S539), 30/30 (D21S11), 11/12 (D5S818), 10/10 (D7S820), 9.3/9.3 (TH01), 8/11 (TPOX), 17/18 (vWA) . All cell cultures were routinely tested for mycoplasma.
All high-grade glioma cultures were generated as previously described 1 . In brief, tissue was obtained from high-grade glioma (WHO grade III or IV) tumours at the time of biopsy or from early post-mortem donations. Tissue was dissociated both mechanically and enzymatically and grown in a defined, serum-free medium designated 'tumour stem media' (TSM), consisting of Neurobasal(-A) (Invitrogen), B27(-A) (Invitrogen), human-bFGF (20 ng ml −1 ) (Shenandoah Biotech), human-EGF (20 ng ml −1 ) (Shenandoah), human PDGF-AA (10 ng ml −1 ) and PDGF-BB (10 ng ml −1 ) (Shenandoah) and heparin (2 ng ml −1 ) (Stem Cell Technologies).
Breast cancer brain metastasis line, PDX DF-BM354, was provided by the Zhao laboratory and developed as previously described 7 . Generation of conditioned medium from acute cortical slices. Conditioned medium was generated as previously described 1 . Mice (genotype varied based on experiment) between the ages of 4-7 weeks were briefly exposed to 4% isofluorane and immediately cervically dislocated and decapitated. Extracted brains were placed in oxygenated high-sucrose solution and sliced in 350-μ m sections. Slices were then placed in buffering solution (aCSF) and allowed to recover for at least 1 h. After recovery, slices were then moved into fresh aCSF in a 24-well plate and slices optogenetically stimulated using a blue-light LED to observe the effects of elevated neuronal activity (in the case of Thy1::ChR2 brain slices) or unstimulated to observe the effects of baseline neuronal activity. After recovery, medium was conditioned for 30 min. For various experiments, conditioned medium was prepared in the presence of various protease inhibitors (described below) or tetrodotoxin at 1 μ M (Tocris). Surrounding medium was then collected for immediate use or frozen at − 80 °C for future experiments. All slice experiments were performed in three biological replicates unless otherwise indicated. EdU incorporation assay. 8-well chamber slides were coated with poly-l-lysine. Cells were then seeded at 40,000 cells per well and exposed to various conditions based off the assay (aCSF, aCSF plus the relevant inhibitor (see below), active conditioned medium (conditioning methods vary by assay), recombinant NLGN3 (Origene Technolgies), NLGN1 (R&D Systems), NLGN4 (R&D Systems), or NLGN4Y (R&D Systems)). 10 μ M EdU was added to each well. Cells were fixed after 24 h using 4% paraformaldehyde in PBS and stained using the Click-iT EdU kit and protocol (Invitrogen). Proliferation index was then determined by quantifying percentage of EdU labelled cells using confocal microscopy at 200× magnification. Group mean differences were otherwise assessed using one-way analysis of variance (one-way ANOVA) with Tukey's post hoc tests to further examine pairwise differences. All experiments were performed in three biological replicates. CellTiter-Glo assay of cell viability. To assess overall cell number, 5,000 glioma cells were seeded in minimal growth medium in a 96-well plate with varying concentrations of ADAM10 inhibitor. After 24, 48 or 72 h, CellTiter-Glo reagent (Promega) was added at a 1:1 ratio. Luminescence was measured after a 10-min incubation at room temperature to stabilize signal. All experiments were performed in three biological replicates. Inhibitors used. Batimastat at 20 nM (Pan MMP inhibitor; BB-94; Selleck Chemicals); MMP2/MMP9 Inhibitor II at 50 nM (sc-311430; Santa Cruz Biotechnology); ARP 100 at 20 nM (MMP2 inhibitor) (R&D Systems); MMP13 Inhibitor at 10 nM (sc-205756; Santa Cruz Biotechnology); MMP9 Inhibitor I at 100 nM (sc-311437; Santa Cruz Biotechnology); MMP9/MMP13 Inhibitor II at 10 nM (sc-311439; Santa Cruz Biotechnology); MMP2/MMP3 Inhibitor I at 20 μ M (sc-295483; Santa Cruz Biotechnology); TAPI-1 at 20 μ M (ADAM17 inhibitor; S7434; Selleck Chemicals); GI254023X at 200 nM unless otherwise indicated (ADAM10 inhibitor; Sigma Aldrich); PF-00562271 at 5 nM (FAK inhibitor; S2672; Selleck Chemicals). Analysis of NLGN3 secretion from glioma. For in vivo studies demonstrating NLGN3 secretion from xenograft-bearing slices, mice were xenografted as above with SU-DIPG-XIII or SU-GBM035 cells in premotor cortex. Brains were extracted and used for conditioned medium experiments in comparison to non-xenografted littermate controls at 5 months (SU-DIPG-XIII) or 6 weeks (SU-GBM035). These experiments were performed in duplicate for SU-DIPG-XIII xenograft-bearing cortical slices and in triplicate for SU-GBM035 xenograft-bearing cortical slices (five biological replicates in total). For in vivo studies demonstrating that neuroligin secretion from xenograft-bearing slices can be blocked by ADAM10 inhibition, mice were xenografted as above with SU-GBM035 cells in premotor cortex and brains were extracted at 6 weeks post xenograft. Cortical slices were made and incubated in the presence or absence of 200 nM ADAM10 inhibitor, GI254023X. Conditioned medium was then analysed using western blot analyses, comparing non-xenograft bearing slices to xenograft-bearing slices from wild-type or Nlgn3 knockout mice in the presence of absence of an ADAM inhibitor. These experiments were performed in triplicate.
For in vitro studies of NLGN3 secretion from glioma cells, SU-pcGBM2 cells were seeded at 5 million cells per well in the presence of either vehicle, 100 nM recombinant NLGN3, 200 nM GI254023X, or 100 nM NLGN3 + 200 nM GI254023X for 48 h. After thorough rinsing of the cells, cells were left in either fresh medium or 200 nM GI254023X for another 48 h. After 48 h, medium was collected and analysed for presence of cleaved NLGN3 using western blot analyses as described below. Experiments were performed in three biological replicates.
The spheroid invasion assay was performed as previously described 12 . Neurosphere formation assay. Extreme limiting dilution analysis (ELDA) was performed to evaluate self-renewal capacity 28 . SU-pcGBM2 cells were dissociated in TrypLE (+ DNase and HEPES) for 5 min at 37 °C. Cells were triturated into a single-cell solution. The solution was incubated with Hoechst (Thermo, 33342) for 30 min at 37 °C. Live cells were identified using a LIVE/DEAD staining kit (Thermo, L10119). Live cells were sorted into 96-well plates. Spheres were counted at 14 days. Cell density per well ranged from 1, 10, 25, 50, 100, 250, 500 to 1,000. Each condition was tested in 10 independent wells. Volume of medium per well was 200 μ l medium with growth factors spike-ins every 3-4 days. The ADAM10 inhibitor was reconstituted in DMSO. Each well was adjusted to have 0.1% DMSO, except for the no-DMSO control wells. Neurosphere-forming capability was determined using the ELDA web-based tool (http://bioinf.wehi.edu.au/software/elda/). Western blot analyses. Western blot analyses were used to probe for protein levels present in either brain slice homogenate or secreted into slice conditioned medium. For slice homogenates, brain slices were lysed using RIPA buffer and protease inhibitors. Lysates were incubated on ice for 10 min and then centrifuged at 10,000g for 10 min at 4 °C. All samples were normalized to protein concentration, mixed with Laemmli loading buffer (1:4), boiled for 5 min, and loaded onto BioRad Mini-Protean TGX precast gels. Protein was transferred to PVDF membranes and blocked with 5% bovine serum albumin (BSA) in TBST for 1 h. Anti-neuroligin-3 (NovusBio; 1:250), anti-phospho FAK pTyr861 (Thermo Fisher Scientific; 1:500), anti-FAK (Cell Signaling Technologies; 1:500), or anti-ADAM10 (Abcam; 1:500) were diluted in 1% BSA/TBST and incubated with the membrane overnight. Secondary anti-rabbit conjugated to horseradish peroxidase (HRP) (BioRad) was then added for 1 h (1:1,000). Proteins were visualized using Clarity ECL Western Substrate (BioRad) and quantified and analysed using ImageJ. Phospho-antibody array. The Phospho Explorer antibody array assay was performed by Full Moon Biosystems on patient-derived paediatric glioblastoma (SU-pcGBM2) cells. Cell lysates were prepared using Protein Extraction Kit (Full Moon BioSystems). Clear supernatant of the lysates was separated, biotinylated, and incubated with Phospho Explorer Antibody Arrays (Full Moon BioSystems) for two hours at room temperature. The array slides were washed with wash buffer (Full Moon BioSystems) and rinsed with DI water. The slides were then incubated with Cy3-Streptavidin for 45 min at room temperature, then washed, rinsed and dried. Arrays were scanned on GenePix Array Scanner (Molecular Devices). Image quantification was performed on GenePix Pro (Molecular Devices). Signal intensity data for each spot on the array was extracted from array images. Since there are two replicates printed for each antibody, the mean signal intensity of the replicates is determined. The data are then normalized to the median value (signal intensity) of all antibodies on the slide. Finally, fold change between control sample and treatment sample is determined using the normalized data (the signal of the treatment sample is divided by the signal of the control sample). Phospho-tyrosine pull-down assay. Samples were analysed using the Cell Signaling Technology PTMScan method as previously described [29] [30] [31] . Cellular extracts were prepared in urea lysis buffer, sonicated, centrifuged, reduced with DTT, and alkylated with iodoacetamide. 15 mg total protein for each sample was digested with trypsin and purified over C18 columns for enrichment with the Phosphotyrosine pY-1000 antibody (8803) and the PTMScan Direct Tyr Kinases Reagent 31 . Enriched peptides were purified over C18 STAGE tips (Rappsilber). Enriched peptides were subjected to secondary digest with trypsin and second STAGE tip before liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis.
Replicate injections of each sample were run non-sequentially for each enrichment. Peptides were eluted using a 90-min linear gradient of acetonitrile in 0.125% formic acid delivered at 280 nl min −1 . Tandem mass spectra were collected in a data-dependent manner with an LTQ Orbitrap Elite mass spectrometer running XCalibur 2.0.7 SP1 using a top-20 MS/MS method, a dynamic repeat count of one, and a repeat duration of 30 s. Real-time recalibration of mass error was performed using lock mass 32 with a singly charged polysiloxane ion m/z = 371.101237.
MS/MS spectra were evaluated using SEQUEST and the Core platform from Harvard University [33] [34] [35] . Files were searched against the NCBI Rattus norvegicus FASTA database updated on 22 May 2015. A mass accuracy of ± 5 p.p.m. was used for precursor ions and 1.0 Da for product ions. Enzyme specificity was limited to trypsin, with at least one LysC or tryptic (K-or R-containing) terminus required per peptide and up to four mis-cleavages allowed. Cysteine carboxamidomethylation was specified as a static modification, oxidation of methionine and phosphorylation on serine, threonine, and tyrosine residues were allowed as variable modifications. Reverse decoy databases were included for all searches to estimate false discovery rates, and filtered using a 5% FDR in the linear discriminant module of Core. Peptides were also manually filtered using a ± 5 p.p.m. mass error range and reagent-specific criteria. For each antibody reagent results were filtered to include only phosphopeptides matching the sequence motif(s) targeted by the antibodies included. All quantitative results were generated using Progenesis V4.1 (Waters Corporation) to extract the integrated peak area of the corresponding peptide assignments. Accuracy of quantitative data was ensured by manual review in Progenesis or in the ion chromatogram files. RNA sequencing. Samples were processed and analysed as previously described 12 with minor modifications as indicated below.
RNA was extracted from Trizol-lysed cells and 1 μ g of total RNA was used for each sample. Polyadenylated RNA was selected using Ambion Dynabeads mRNA Purification Kit (Life Technologies, 61006) and fragmented with fragmentation buffer (Ambion, AM8740). First strand synthesis was performed using Random Hexamer Primers (Invitrogen, 48190-011) and SuperScript II (Invitrogen, 18064-014). Second-strand synthesis was performed using DNA Pol I (Invitrogen, 18010-025) and RNA was removed using RNaseH (Invitrogen, 18021-014).
Libraries were end-repaired, 3′ A-tailed, and ligated to NEBNext Multiplex Oligo Adaptors (NEB E7335S). Sequencing was performed on an Illumina NextSeq 500 by Stanford Functional Genomics Facility.
Reads were mapped to hg19 annotation using Tophat2 36 (version 2.0.13) and transcript expression was quantified against RefSeq gene annotations using featureCounts 37 . Differential testing and log2 fold change calculation was performed using DESeq2 38 with default multiple hypothesis adjustment to reduce false positives (Benjamini-Hochberg, FDR = 0.1). Gene Ontology analyses were performed using DAVID 39, 40 .
LC-MS/MS analysis of GI254023X concentrations in tissues and serum.
A single 100 mg kg −1 dose was delivered intraperitoneally in NSG mice, and tissue samples collected 30 min later for analysis using LC-MS/MS. Tissues samples were weighed and 1 volume of bullet blender beads (Next Advance) and 3 volume of Milli-Q water were added. Tissues were homogenized by a bullet blender (Next Advance) at 4 °C according to manufacturer's instruction. The neat stock solution of GI254023X was dissolved in DMSO at 5 mg ml −1 and further diluted in 50% methanol to prepare spiking solutions. For spiked standard curve, 25 μ l of GI254023X spiking solutions (0.5-1,000 ng ml −1 for brain samples and 1-100 μ g ml −1 for serum and kidney samples) was mixed with 25 μ l of blank tissue homogenate or serum. For samples, the spiking solution was replaced by 25 μ l of 50% methanol to make up the volume. After vortexing all standards and samples, 150 μ l of methanol/acetonitrile 20:80 (v/v) was added to the mixture and vortexed vigorously for 1 min followed by centrifugation at 3,000g for 10 min. The supernatant was diluted 3 times in Milli-Q water for brain samples and 100 times in 25% methanol for serum and kidney samples. The LC-MS/MS system consists of a QTRAP 4000 mass spectrometer (AB SCIEX) coupled to a Shimadzu UFLC system. LC separation was carried out on a ZORBAX SB-Phenyl column (4.6 mm × 50 mm, 3.5 μ m) (Agilent) at room temperature. The analysis time was 3 min. The injection volume was 5-10 μ l. Isocratic elution was carried out with a mobile phase composed of 55% water and 45% acetonitrile with 0.1% of formic acid and a flow rate of 0.5 ml min −1 . The mass spectrometer was operated in the positive mode with multiple-reaction monitoring (MRM) with the transition m/z 392.2 to 361.2. Data acquisition and analysis were performed using the Analyst 1.6.1 software (AB SCIEX). LC-MS/MS analysis of INCB7839 (Aderbasib) and XL-784 in brain tissue and serum. INCB7839 was purchased from Astatech, XL-784 was provided by True Pharmachem. A single 50 mg kg −1 dose of INCB7839 (aderbasib) or XL-784 was delivered intraperitoneally in NSG mice, and tissue samples collected at various time points for analysis using LC-MS/MS. NSG mice were purchased from the letter reSeArCH Model Animal Research Center of Nanjing University. Study was conducted by Crown Biosciences, in accordance with a protocol approved by the Institutional Animal Care and Use Committee (IACUC) of CrownBio and in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). Compounds were formulated in 2% DMSO, 2% Tween 80, 48% PEG300, 48% water. Compounds were administered intraperitoneally, with a dosing volume of 10 μ l g −1 and concentration of 5 mg ml −1 . Compounds were dosed at 50 mg kg −1 . A cohort of 24 male, NSG mice, age 6-8 weeks, body weight 18-22 g, were used for each study. Animals were housed at room temperature, under 40-70% humidity, with a 12 h light/12 h dark schedule. Mice were fed with Co 60 dry granule food, with free access to reverse osmosis water. Eight time points were collected for each compound (0.25, 0.5, 1, 2, 4, 6, 8 and 24 h), with an n = 3 for each time point. Blood was collected via cardiac puncture and collected into potassium-EDTA Eppendorf tubes. Samples were centrifuged within 30 min to afford plasma samples. Brains were collected at each time point, PBS (4× ) was added, and the material homogenized with a Tissue Lyser II to give a fine homogenate. Brain homogenate (50 μ l) was treated with 250 μ l acetonitrile (containing 200 ng ml −1 tolbutamide), which was then vortexed and then centrifuged at 4,000 r.p.m. (3220g) for 20 min. The supernatant was collected and mixed with a 0.1% aqueous formic acid solution. Samples were analysed on a Waters UPLC or Agilent 1200 Liquid chromatography system, with an API 4000 mass spectrometer, and a 10 μ l injection volume, with tolbutamide as an internal standard. Pharmacokinetics were analysed using WinNonlin6.3 (non-compartmental model). Mouse drug treatment studies. For all drug studies, NSG mice were xenografted as above with either SU-pcGBM2, SU-DIPG-VI, or SU-DIPG-XIX cells. Four weeks post-xenograft, animals were treated with either systemic administration of ADAM10 inhibitor, GI254023X (Sigma-Aldrich; formulated in 10% DMSO in 0.1M carbonate buffer) via intraperitoneal injection 5 days per week at 100 mg kg −1 or systemic administration of ADAM10/17 inhibitor, INCB7839 (Astatech, Inc.; formulated in 2% DMSO, 2% Tween 80, 48% PEG300, 48% water) via intraperitoneal injection 5 days per week at 50 mg kg −1 . For both studies, controls were intraperitoneally injected with an identical volume of vehicle. Drug treatment began four weeks after xenografting and continued through week six. Bioluminescence imaging was performed by a blinded investigator before treatment, and again 7 and 14 days later, using an IVIS imaging system (Xenogen) under isoflurane anaesthesia. Similar to above, tumour burden was assessed as fold change in total flux from the beginning to end of treatment. All differences were statistically verified using a Student's two-tailed t-test. Confocal imaging and quantification of cell proliferation. Cell quantification was performed by a blinded investigator using live counting at 400× magnification using a Zeiss LSM700 scanning confocal microscope and Zen 2011 imaging software (Carl Zeiss). The area for quantification was selected as follows: of a 1 in 6 series of 40-μ m coronal sections, 3 consecutive sections were selected at approximately 1.1-0.86 mm anterior to bregma (figures 22, 23 and 24 of Franklin and Paxinos 41 ); using our stereotactic coordinates for tumour xenograft, these sections are expected to include the tissue most proximal to the site of tumour cell implantation in the coronal plane. For each of the three consecutive sections, the cingulum bundle was first identified as an anatomic landmark, and six 160 × 160-μ m field area for quantification were selected centred around this landmark within cortical layer 6b of M2. Within each field, all human nuclear antigen (HNA)positive tumour cells were quantified to determine tumour burden within the areas quantified. HNA-positive tumour cells were then assessed for double-labelling with Ki67. To calculate the proliferation index (the percentage of proliferating tumour cells for each animal), the total number of HNA-positive cells co-labelled with Ki67 across all areas quantified was divided by the total number of human nuclei-positive cells counted across all areas quantified. Differences in proliferation indices were calculated using unpaired, two-tailed Student's t-tests (parametric data) or Mann-Whitney test (non-parametric data).
Statistical analyses. Statistical tests were conducted using Prism (GraphPad) software unless otherwise indicated. Gaussian distribution was confirmed by the Shapiro-Wilk normality test. For parametric data, unpaired, two-tailed Student's t-tests and one-way ANOVA with Tukey's post hoc tests to further examine pairwise differences were used. For non-parametric data, two-sided Mann-Whitney test was used. The limiting dilution assay to test for neurosphere forming capacity was analysed with a chi-squared test using the ELDA web-based tool (http://bioinf.wehi. edu.au/software/elda/). A level of P < 0.05 was used to designate significant differences. On the basis of the variance of xenograft growth in control mice, we used at least 3 mice per genotype to give 80% power to detect an effect size of 20% with a significance level of 0.05. For all animal experiments, the number of independent mice used is listed in figure legend. For all western blots, analyses were done in biological triplicate, except in the case of Fig. 2d, e and Extended Data Fig. 6a , in which analyses were done in biological duplicates and technical triplicates.
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Experimental design 1. Sample size
Describe how sample size was determined. Based on the variance of xenograft growth in control mice, power calculations indicated use of at least 3 mice per genotype to give 80% power to detect an effect size of 20% with a significance level of 0.05
Data exclusions
Describe any data exclusions. No data were excluded from the analyses.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For patient-derived xenograft studies, animals were IVIS imaged at baseline and randomized based on tumor size by a blinded investigator so that experimental groups contained an equivalent range of tumor sizes.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The experimenter performing IVIS imaging and histological quantifications was blinded to group allocation.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
